| Revenue growth | 23% YoY revenue growth to ₹6,813 crore in FY26. |
|---|---|
| Margins | EBITDA margins expanded 6.7% points to 26.8% due to mix. |
| Demand visibility | Strong visibility for CDMO; servicing 1/3rd of global HIV population. |
| Management confidence | Balanced confidence; shifting focus to high-growth CDMO and new modalities. |
Growth
FY26 revenue reached ₹6,813 crore, driven by a 38% surge in small molecule CDMO and affordable medicines growth.
Outlook
Guided 50% CDMO revenue share by 2030; ₹3,000 crore capex planned over the next two years.
Risks
Geopolitical disruptions affecting raw material logistics; high capex intensity may pressure near-term free cash flow.
Earnings Call filed with BSE, NSE: LAURUSLABS. Summary written with AI assistance from the document.
Laurus Labs Ltd: key numbers
- Share price
- ₹2,007.00
- Market cap
- ₹1,08,441 Cr
- Revenue (annual)
- ₹6,813 Cr
- Net profit (annual)
- ₹888.8 Cr
- P/E (TTM)
- 99.2×Sector 50.4×
- Promoter holding
- 27.47%-0.02% QoQ
- FII holding
- 28.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Laurus Labs Ltd
All →Laurus Labs Investor Presentation: Key Takeaways
Laurus Labs delivered record Q1FY27 revenue of ₹2,026 Cr, a 29% YoY increase, driven by robust CDMO growth. EBITDA margins expanded 700 bps YoY to 31.8% on favorable mix.
Laurus Labs Earnings Call Transcript: Key Takeaways
Laurus Labs delivered record quarterly revenue and EBITDA margins, driven by strong CDMO commercial supplies and recovery in the affordable medicine portfolio.
- Call
- Guides 50% growth
Laurus Labs Investor Presentation: Key Takeaways
Laurus Labs delivered a strong Q1 FY27 with ₹2,026 Cr revenue (up 29% YoY), driven by robust CDMO growth. EBITDA margins expanded to 31.8% due to favorable product mix and operational leverage.
Laurus Labs Q1 FY27 Results: Net Profit ₹362.1 Cr, Up 123.9% YoY
Laurus Labs Ltd reported revenue from operations of ₹2,026 Cr (+29.1% YoY) and net profit of ₹362.1 Cr (+123.9% YoY) for Q1 FY27.
- Key figure
- Net profit ₹362.1 Cr · +123.9% YoY
Laurus Labs Earnings Call: Key Takeaways
Laurus Labs delivered strong Q4 FY26 results with 23% annual revenue growth and significant EBITDA margin expansion to 26.8%, driven by a transforming CDMO business and generic portfolio ramp-up.
Laurus Labs Earnings Call: Key Takeaways
Laurus Labs delivered record FY26 results with Revenue up 23% and Net Profit surging 148%, driven by a significant 36% jump in CDMO and improved operating leverage.